Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Fuse Medical's annualizedNet Income for the quarter that ended in Jun. 2023 was $1.23 Mil. Fuse Medical's average total tangible assets for the quarter that ended in Jun. 2023 was $15.76 Mil. Therefore, Fuse Medical's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2023 was 7.82%.
The historical rank and industry rank for Fuse Medical's Return-on-Tangible-Asset or its related term are showing as below:
FZMD's Return-on-Tangible-Asset is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 0.665 * Ranked among companies with meaningful Return-on-Tangible-Asset only.
Fuse Medical (OTCPK:FZMD) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Fuse Medical Return-on-Tangible-Asset Related Terms
Fuse Medical Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Fuse Medical's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FZMD vs GTHP, SONX, PBIO: Return-on-Tangible-Asset Comparison
For the Medical Devices subindustry, Fuse Medical's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fuse Medical Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Fuse Medical's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Fuse Medical's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2023) net income data.
What does a Return-on-Tangible-Asset of 7.82% mean?
Fuse Medical (FZMD) has a Return-on-Tangible-Asset of 7.82% as of Jun. 2023. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Fuse Medical and its competitors.
Is Fuse Medical's Return-on-Tangible-Asset too high?
Fuse Medical's current Return-on-Tangible-Asset is 7.82%. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.67. Fuse Medical's value of 7.82% is 1075.9% above this industry median. Overall, Fuse Medical has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Fuse Medical's Return-on-Tangible-Asset compare to GTHP and SONX?
Fuse Medical's Return-on-Tangible-Asset of 7.82% can be compared against companies in the Medical Devices & Instruments industry. The industry median Return-on-Tangible-Asset is 0.67. Fuse Medical's value of 7.82% is 1075.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.67, based on 856 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fuse Medical's current Return-on-Tangible-Asset of 7.82% is 1075.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Fuse Medical and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fuse Medical's current Return-on-Tangible-Asset is 7.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fuse Medical stock overvalued right now?
Fuse Medical (FZMD) has a current Return-on-Tangible-Asset of 7.82%. The current Return-on-Tangible-Asset is 7.82% and 1075.9% above the Medical Devices & Instruments industry median of 0.67. Fuse Medical's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Fuse Medical (FZMD), the current Return-on-Tangible-Asset is 7.82% as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Fuse Medical Inc is a manufacturer, distributor, and wholesaler of medical device implants, offering portfolio of orthopedic implants and biologics including: internal fixation products, upper and lower extremity plating and total joint reconstruction implants, soft tissue fixation and augmentation for sports medicine procedures, spinal implants for trauma, degenerative disc disease and deformity indications, and osteo-biologics, regenerative and connective tissues, which include human allografts, substitute bone materials, tendons, and regenerative tissues. Its portfolio of Orthopedic Implants and Biologics provide products to assist surgeons with positive patient outcomes and cost-effective solutions for its customers including hospitals, medical facilities, and sub-distributors.
12GF Score
Get the complete analysis for FZMD
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FZMD has been successfully added to your 
